Building and Using an Immune Cell Model to Predict How Well PD-1 Monoclonal Antibody Works for Advanced Esophageal Cancer

What this Trial Is About

Researchers are studying 200 patients with advanced esophageal squamous cell carcinoma who are receiving PD-1 monoclonal antibody treatment combined with chemotherapy. The goal is to analyze changes in immune cells in the blood before and after treatment using machine learning to build a model that predicts how well the PD-1 antibody works. The study will also compare this blood-based model with PD-L1 expression in tumor tissue to guide treatment choices and improve therapy outcomes. Patients will be divided into two groups based on their response to treatment reactive or non-reactive. The study focuses on observing immune cell changes and treatment effects without testing new drugs or interventions. This observational study will track patients over several years, starting from 2022 to 2026. Participants will undergo regular blood tests to measure immune cells and immune molecules, along with imaging exams throughout the study period. Researchers will monitor treatment response, immune changes, and safety during this time. The study intends to provide important information about predicting treatment effectiveness in advanced esophageal cancer over a long follow-up.

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody